Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 946-950

  Rosenberg, J E ^a   Halabi, S ^b   Sanford, B L ^c   Himelstein, A L ^d   Atkins, J N ^e   Hohl, R J ^e   Millard, F ^f   Bajorin, D F ^g   Small, E J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HELEN F GRAHAM CANCER CENTER   (United States)

^d Southeast Cancer Control Consortium   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Bortezomib; Proteasome; PS 341; Salvage therapy; Urothelial carcinoma

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEASOME INHIBITOR;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLADDER CANCER; BLOATING; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HICCUP; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; LETHARGY; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; METABOLIC DISORDER; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROTOXICITY; ODYNOPHAGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPONSE TIME; SALVAGE THERAPY; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE DISEASE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; VISCERAL METASTASIS; VOMITING;

EID: 43049129660     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm600     Document Type: Article

References (19)

1. A. Jemal R. Siegel E. Ward Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
2. H. von der Maase L. Sengelov J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
3. A. Mani E.P. Gelmann The ubiquitin-proteasome pathway and its role in cancer J Clin Oncol 23 2005 4776 4789
4. Y.H. Ling L. Liebes B. Ng PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis Mol Cancer Ther 1 2002 841 849
5. X.Y. Pei Y. Dai S. Grant The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells Leukemia 17 2003 2036 2045
6. P.M. Voorhees E.C. Dees B. O'Neil R.Z. Orlowski The proteasome as a target for cancer therapy Clin Cancer Res 9 2003 6316 6325
7. J Adams. Proteasome Inhibitors in Cancer Therapy. Totowa, NJ: Humana Press 2004
8. C. Aghajanian S. Soignet D.S. Dizon A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2002 2505 2511
9. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
10. D.F. Bajorin P.M. Dodd M. Mazumdar Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
11. J. Brown J. Von Roenn R. O'Regan A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC) J Clin Oncol 22 2004 (Abstr 546)
12. C.H. Yang A.M. Gonzalez-Angulo J.M. Reuben Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits Ann Oncol 17 2006 813 817
13. M.H. Shah D. Young H.L. Kindler Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors Clin Cancer Res 10 2004 6111 6118
14. N. Svetomir S.M. Geyer F. Dawkins A phase II study of bortezomib in the treatment of metastatic malignant melanoma Cancer 103 2005 2584 2589
15. N.B. Davis D.A. Taber R.H. Ansari Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study J Clin Oncol 22 2004 115 119
16. G.V. Kondagunta B. Drucker L. Schwartz Phase II trial of bortezomib for patients with advanced renal cell carcinoma J Clin Oncol 22 2004 3720 3725
17. J. Johl K. Chansky P.N. Lara The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial J Clin Oncol 23 2005 (Abstr 7047)
18. G. Gomez-Abuin E. Winquist W.M. Stadler A phase II study of PS-341 (bortezomib) in advanced or metastatic urothelial cancer: a trial of the Princess Margaret Hospital and University of Chicago phase II consortia Invest New Drugs 25 2007 181 185
19. R.Z. Orlowski T.E. Stinchcombe B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 2002 4420 4427